AstraZeneca Pharma India Limited has informed the Exchange about General Updates

Regulatory Product ApprovalBusiness Updates View source PDF Explain this filing

ASTRAZEN · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close

-0.3%Reaction day

₹8160.00

prior close

₹8210.50

announcement price

In-mkt

timing

Nifty Microcap 250market · in no size index; the smallest one is used-0.8%+0.5% vs market

Pharmaceuticals peers, median of 145sector-1.3%+0.9% vs sector

On the reaction day the stock moved 0.5 pts more than Nifty Microcap 250 and 0.9 pts more than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark

Stock

+0.1

10m

-0.1

15m

-0.1

30m

-0.1

Sessions after the filingfrom the prior close

StockMarketvs marketSectorvs sector

Reaction day

-0.3-0.8+0.5-1.3+0.9

Next day

-2.0-1.0-1.1-1.8-0.3

-0.8+3.6-4.4+1.5-2.3

-0.0+5.3-5.4+2.5-2.6

-1.3+7.0-8.4+3.4-4.7

-2.6+8.1-10.7+4.1-6.7

-2.3+10.2-12.6+6.1-8.4

15d

-3.2+11.8-15.0+7.2-10.3

+22.8+14.6+8.2+6.1+16.7

+11.9+15.3-3.3+6.4+5.5

+7.1+10.2-3.1+4.1+3.0

UpDownMarket · Nifty Microcap 250Sector · Pharmaceuticals peers, median of 145Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

AstraZeneca Pharma India has received approval from India's drug regulator CDSCO to import and distribute Enhertu (Trastuzumab deruxtecan) for an additional indication in India. The expanded approval covers the use of Enhertu as a monotherapy for adult patients with unresectable or metastatic HER2-low or HER2-ultralow breast cancer who have received at least one prior endocrine therapy. This widens the patient population eligible for Enhertu beyond the previously approved HER2-positive cases. Marketing in India for this new indication is subject to receipt of any additional statutory approvals.

Likely market impact

This is a positive development as it broadens the addressable market for a key oncology drug in AstraZeneca's portfolio, potentially driving incremental revenue growth in India. The expanded label could enhance Enhertu's commercial potential in the country's growing oncology segment.